Abstract
Treatment results of human hepatoblastoma (HB) have been improved remarkably during recent years, mainly through the establishment of integrated regimens controlled and coordinated by multicentric treatment studies. Today, neoadjuvant and adjuvant chemotherapy is combined with surgical resection of the tumors. The main therapeutic goal is a complete surgical removal of tumor masses, which is also essential for the survival of the patients. Despite improved overall survival rates, treatment results of advanced tumors are still far from being satisfying. Multidrug resistance has been identified as a major factor responsible for the bad prognosis of children suffering from advanced staged hepatoblastoma. During recent years investigations focused on factors contributing to drug resistance in hepatoblastoma and on possible approaches towards overcoming this therapeutical challenge. Alternative approaches that are currently evaluated in experimental and clinical settings comprise new cytotoxic agents, chemosensitizers, gene directed applications but also surgical techniques and an expansion of indication for liver transplantation.
Keywords: P-Glycoprotein, MDR1 gene expression, Glutathione S-Transferase Micro, chemoresistance, Bcl-2 gene, TOPO II enzyme
Current Pharmaceutical Biotechnology
Title: Drug Resistance in Hepatoblastoma
Volume: 8 Issue: 2
Author(s): S. W. Warmann and J. Fuchs
Affiliation:
Keywords: P-Glycoprotein, MDR1 gene expression, Glutathione S-Transferase Micro, chemoresistance, Bcl-2 gene, TOPO II enzyme
Abstract: Treatment results of human hepatoblastoma (HB) have been improved remarkably during recent years, mainly through the establishment of integrated regimens controlled and coordinated by multicentric treatment studies. Today, neoadjuvant and adjuvant chemotherapy is combined with surgical resection of the tumors. The main therapeutic goal is a complete surgical removal of tumor masses, which is also essential for the survival of the patients. Despite improved overall survival rates, treatment results of advanced tumors are still far from being satisfying. Multidrug resistance has been identified as a major factor responsible for the bad prognosis of children suffering from advanced staged hepatoblastoma. During recent years investigations focused on factors contributing to drug resistance in hepatoblastoma and on possible approaches towards overcoming this therapeutical challenge. Alternative approaches that are currently evaluated in experimental and clinical settings comprise new cytotoxic agents, chemosensitizers, gene directed applications but also surgical techniques and an expansion of indication for liver transplantation.
Export Options
About this article
Cite this article as:
Warmann W. S. and Fuchs J., Drug Resistance in Hepatoblastoma, Current Pharmaceutical Biotechnology 2007; 8 (2) . https://dx.doi.org/10.2174/138920107780487456
DOI https://dx.doi.org/10.2174/138920107780487456 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Current Enzyme Inhibition A Review of the Current Role of Proton Therapy in Modern Oncology
Current Drug Therapy MAVS: A New Weapon in the Fight Against Viral Infections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) mRNA as a Therapeutic Target in Lung Disease
Drug Design Reviews - Online (Discontinued) Graphene and Graphene Oxide as a Docking Station for Modern Drug Delivery System
Current Drug Delivery Gallium-68 in Medical Imaging
Current Radiopharmaceuticals Effects of Vector Fusion Peptides on the Conformation and Immune Reactivity of Epitope-Shuffled, Recombinant Multi-Epitope Antigens
Protein & Peptide Letters Cadmium-containing Quantum Dots: Current Perspectives on Their Application as Nanomedicine and Toxicity Concerns
Mini-Reviews in Medicinal Chemistry <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery